New Hope for Fatal Brain Tumor Offered by UC San Diego Moores Cancer Center

Jim Black is combating recurrent glioblastoma multiforme (GBM), the toughest, most aggressive, usual kind of brain tumor in the United States.

Jim Black is combating recurrent glioblastoma multiforme (GBM), the toughest, most aggressive, usual kind of brain tumor in the United States. In the United States, each year, approximately 10,000 patients are affected by GBM. Now, a novel investigational device – available only at clinical trial sites – is offering new hope to these patients.

The non-invasive procedure – called Tumor Treating Fields (TTF) – is delivered using a portable device – called the NovoTTF-100A System made by Novocure. The TTF procedure uses alternating electrical fields to disrupt the rapid cell division exhibited by cancer cells.

Diagnostic Brain Tumour Test Can Perhaps Modernize Patients� Care
Researchers at UT Southwestern Medical Centre have devised what they consider as the first clinical application of a new imaging technique to diagnose brain tumours.

"Patients with recurrent GBM present a significant treatment challenge," said Santosh Kesari, MD, PhD, director of Neuro-Oncology at UC San Diego Moores Cancer Center. "The initial clinical research for the approval trial demonstrated that, compared to patients who were treated with chemotherapy, patients treated with NovoTTF achieved comparable survival times, had fewer side effects, and reported improved quality of life."

On average, a patient with GBM survives less than 15 months with optimal treatment and only three to five months without additional effective treatment. The TTF procedure may provide physicians with a fourth treatment option in addition to surgery, radiation therapy and chemotherapy.

TTFs inhibit tumor growth by causing cancerous cells to die. The TTF procedure is delivered using non-invasive, insulated transducer arrays (electrodes) that are placed directly on the skin in the region of the tumor. The hat-like collection of electrodes connects to a portable device which is slightly thicker than a laptop and weighs about six pounds. The device sends a low intensity, alternating electric field into the tumor which prevents the cells from dividing and spreading and causes cancer cells to die.

Earlier Detection of Brain Tumours' Response to Therapy on the Anvil
Researchers at Barrow Neurological Institute at St. Joseph's Hospital and Medical Centre suggest that a certain type of scanning can detect when a patient is failing brain tumour treatment

The most commonly reported side effect from NovoTTF is a mild-to-moderate scalp rash, beneath the electrodes. The FDA-approved device is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

"When all other options have been exhausted, patients are willing to do just about anything to keep the tumor at bay," said Kesari. "This device gives them an opportunity to fight back, to feel like they are taking an active, hands-on role in their own treatment, and provides tremendous hope."

First Non-invasive NPC Biomarker Discovered
(CSHL) have identified and validated the first biomarker that permits neural stem and progenitor cells (NPCs) to be tracked non-invasively in the brains of living human subjects.

Source-Eurekalert

Low-radiation treatment for brain tumours
A new method of treating childhood brain tumours, aimed at reducing the risk of damage to normal tissue, is to be trialled at hospitals around the US.